FILTER
FILTERED INTERVIEW RESULTS
Doug Ramshaw
PRESIDENT, MINERA ALAMOS
Minera Alamos outlines progress at its Santana gold project in Mexico.
Theo Yameogo
CO-LEADER – MINING AND METALS CANADA, ERNST & YOUNG
EY explains to GBR how the COVID-19 pandemic must accelerate the adoption of digitalization and other disruptive technologies by the mining industry.
Keith Spence
PRESIDENT & CEO, GLOBAL MINING CAPITAL CORP.
Global Mining Capital Corp. speaks about the prospects of gold and of China’s role as a foreign investor.
Anthony (Tony) Makuch
PRESIDENT AND CEO, KIRKLAND LAKE GOLD
Kirkland Lake Gold explains how it gets the best out of its assets.
Jago Penrose
CMO, GREEN RESOLUTION
Green Resolution explains its sustainability-incentivized bioremediation technology that it is introducing to treat Canada’s mine tailings.
Randy Smallwood
PRESIDENT & CEO, WHEATON PRECIOUS METALS
WPM predicts that its portfolio of precious metal streams is entering a ‘harvest period’.
Stephen G. Roman
PRESIDENT & CEO, GLOBAL ATOMIC CORPORATION
Global Atomic Corporation is a Canadian company trading on the TSX that is advancing the high-grade, large DASA uranium deposit in the Republic of Niger and has a share in a zinc concentrate production facility in Turkey.
Justin Cochrane
PRESIDENT & CEO, CONIC METALS CORP.
Conic Metals recently became public and holds numerous royalties in nickel and cobalt.
Bob Masterson
CEO, CHEMISTRY INDUSTRY ASSOCIATION OF CANADA (CIAC)
CIAC explains the current evolution of Canada’s industrial chemicals segment.
Denis S. Frawley
PARTNER, ORMSTON LIST FRAWLEY LLP
Ormston List Frawley is a law firm that specializes in the mining industry, notably helping junior and exploration-stage mining companies with legal and back-office functions.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
